Fate Therapeutics and Janssen Biotech (J&J) announced a worldwide collaboration to develop iPSC-derived CAR NK and CAR T-cell product candidates against up to four tumor-associated antigens. Fate received $50M upfront cash plus $50M equity investment, with eligibility for up to $1.8B in development/regulatory and $1.2B in commercial milestones, plus double-digit royalties. Janssen funded R&D through IND.
Key facts
AnnouncedApr 02, 2020
Deal value$3.1B
Deal typeCo-Development
Therapeutic areaHematologic malignancies and solid tumors
IndicationsHematologic malignancies and solid tumors
Key assetsiPSC-derived CAR NK and CAR T-cell candidates